Nektar Therapeutics
- اسفند- 1396 -1 اسفنددیگر
Merck inks $394M takeover of oncolytic virus play Viralytics
Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with…
-- بیشتر بخوانید -- - آذر- 1396 -18 آذردیگر
?Nektar Therapeutics: Could Improved FDA Policies Help NKTR-181
Summary Prescription opioid abuse leads to opioid overdoses. Abusers tend to shift toward using illicit drugs over time. US FDA is lowering the hurdles for…
-- بیشتر بخوانید -- - 18 آذر
Notable BioSci Mover On Dec. 7, 2017 – Nektar Therapeutics
Summary Nektar continues to appreciate shareholders as the market and analysts are viewing the firm favorably. NDA for NKTR-181 will be filed in April 2018…
-- بیشتر بخوانید --
